Armata Pharmaceuticals (ARMP) revenue and earnings history
Armata Pharmaceuticals's annual figures for 12 fiscal years, as filed with the SEC.
Revenue and net income, 12 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | — | −$36.6M | −$174M | −$25.8M | $542K | −$26.3M | $2.61M | — | — | $8.69M | — | 10-K |
| 2024ended Dec 31, 2024 | — |
The latest quarter, insider trades and fund moves: Armata Pharmaceuticals (ARMP) on OQRO.
Common questions
Has Armata Pharmaceuticals been profitable?
It reported a net loss in 11 of the years shown (2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025). The highest net income was $23.1M in fiscal 2014.
What was Armata Pharmaceuticals's free cash flow in fiscal 2025?
−$26.3M: operating cash flow of −$25.8M minus capital expenditure of $542K. OQRO calculates free cash flow this way from the two filed lines.
How much cash has Armata Pharmaceuticals returned to shareholders?
Its cash-flow statements show $80K in dividends over 1 fiscal year ($0 in fiscal 2025). These are the dollar amounts paid in each year, as filed; a year with no figure means none was tagged.
Where these figures come from
The SEC’s companyfacts data: every figure Armata Pharmaceuticals tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
